Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] Adalimumab in paediatric psoriasis

Psoriasis is an immune-mediated chronic disease affecting the skin and joints and multiple other organs including the heart.1 Although it affects about 2% of the population worldwide,2 the prevalence of paediatric psoriasis is 0·70%,3 as most patients initially present with the disease in adulthood. There is a paucity of approved systemic therapies for the management of paediatric psoriasis. Systemic treatments include, among others, methotrexate, ciclosporin, acitretin,4 etanercept (a tumour necrosis factor [TNF]-α antagonist approved by the US Food and Drug Administration in November, 2016, to treat moderate to severe psoriasis in children aged 4–17 years), and adalimumab (another TNF-α antagonist approved in 2015 by the European Medicines Agency for the treatment of severe plaque psoriasis in children aged 4 years or older).